However, many reported studies of ABMT in NHL are flawed by short follow-up, small patient numbers and lack of a uniform transplant preparative regimen. Essentially no Few series describing the results of autologous bone marrow transplantation (ABMT) for the treatment of literature exists addressing the clinical care of patients who achieve complete remission after transplantation. relapsed after initial induction chemotherapy, or failed to histologies, eight of eight with IBL remain in continued achieve complete remission with initial induction chemoremission, while four of 14 with LCL relapsed 24-48 therapy. All but two relapsed patients were treated with months after ABMT. We conclude that patients with additional chemotherapy and reassessed to determine high-grade histologic subtypes of NHL who are in comwhether their disease was 'sensitive' or 'resistant'. Sensiplete remission 2 years after ABMT are likely to be tive disease was defined as regression of tumor size by at cured. However, patients with intermediate and lowleast 50% after chemotherapy. Eligibility criteria included grade histologic subtypes are at continued risk of a cardiac ejection fraction of Ͼ50%, single breath carbon relapse and require appropriate clinical surveillance for monoxide diffusing capacity (corrected for hemoglobin) at least 48 months after ABMT.
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1992, as our standard of clinical practice was evolving to Follicular mixed 6 (5.5) the use of PBPC as the sole source of hematopoietic rescue Follicular large cell 10 (9) following high-dose preparative regimen.
Diffuse small cleaved 6 (5.5) Diffuse mixed 3
Patients were hospitalized for the delivery of high-dose Diffuse large cell 40 (36) chemotherapy, and were discharged after adequate hematoDiffuse immunoblastic 19 (17) logic recovery occurred. Platelets or RBC transfusions were Lymphoblastic 8 (7) administered when the platelet count was Ͻ15 000/l or Small non-cleaved 2
hemoglobin Ͻ8.5 gm/dl respectively. All blood products Total 110 (100)
were irradiated before infusion. Broad spectrum antibiotics were administered for febrile neutropenic episodes. Patients also received prophylactic low dose Amphotericin-B (0.1 mg/kg/day starting on day +1). 
Bone marrow or PBPC processing and supportive care
Prior to 1991, patients received autologous bone marrow alone without the infusion of post-transplant cytokines. In 1991 to 1993, patients received G-CSF primed peripheral blood progenitor cells with or without autologous bone marrow, with G-CSF starting on day +1 after transplantation. The dose of G-CSF for priming was 5 g/kg/day × 7 dose of G-CSF after transplantation was 16 g/kg/day until variable in the multivariate analysis was the number of courses of prior chemotherapy. We compared those patients receiving one course of prior chemotherapy (n = 38) to those patients with two or more courses of prior chemotherapy (n = 72). Overall survival and relapse-free survival was 61% and 51% for those patients receiving one or fewer courses of prior chemotherapy, compared to 44% and 27% for those receiving two or more courses.
Extended follow-up
Forty-seven patients were in complete remission (CR) 2 years after transplantation. We analyzed the outcome of We then analyzed the subgroup of diffuse large cell lymtime to relapse is 5 months, ranging from 1-40 months.
phomas. Fourteen patients with diffuse large cell lymphoma Median time to relapse for low, intermediate, and highwere in CR at 24 months, and four have relapsed; eight grade histologies was 19 (range 1-33 months), 7 (2-40 patients with diffuse immunoblastic large cell lymphoma months), and 2 (1-9 months) respectively. The difference were in CR at 24 months, and none have relapsed. The in time to relapse between low (19 months) and high-grade difference between these two histologic subtypes was not (2 months) histologies was statistically significant (P = statistically significant (P = 0.10), probably due to the small 0.02). Two-year relapse-free survival by histology is shown numbers of patients. in Table 3 . Table 4 shows variables tested to be predictive of improved relapse-free survival. An elevated LDH at the Discussion time of ABMT was the most powerful negative prognostic feature, with overall survival and relapse-free survival for Little, if any, data exist describing cost-effective care for those with a normal LDH at the time of transplant of 65% patients with NHL after ABMT. We found that 100% of and 47%, compared with overall survival and relapse-free patients with high-grade lymphoma, if in complete survival of 17% and 17%, respectively for patients with an remission 2 years post-ABMT, remain so with extended elevated LDH at the time of BMT. We applied the agefollow-up. In contrast, patients with low and intermediateadjusted international prognostic index described by Shipp grade NHL were at continued risk of relapse greater than et al (based on tumor stage, LDH level, and performance 2 years after ABMT. This finding has potential clinical status) 39 comparing patients with zero or one risk factor to implications with respect to patient surveillance. Asymptothose with two or three factors at the time of transplant. matic post-BMT patients are routinely restaged at periodic The Shipp index was a significant univariate variable, but intervals, usually with repeated CT scans of the chest, abdodid not achieve statistical significance when a multivariate men and pelvis. The duration of this surveillance strategy analysis was performed. The other statistically significant is generally 5 years after the cessation of active therapy. Whether this surveillance strategy is logical after transplantation has never been adequately assessed. Based on our NHL, 20 occurred within 1 year of transplant. 27 Vose et plantation has been described by others. 5, 7 Our series found that chemosensitive disease was of borderline significance in sensitive relapse fare statistically significantly better than do those transplanted in resistant relapse. 3, 11, 13, 15, 19, 24, 27 However, our series had only 15 patients transplanted with disease. The median time from transplantation to proresistant disease, resulting in low statistical power to detect gression was 2 months for patients with high-grade, 3 a difference between the sensitive and resistant groups. months for patients with intermediate-grade, and 11 months In summary, our data document the importance of longfor low-grade NHL patients. Bastion et al 36 reported a serterm follow-up in interpreting the results of ABMT in ies of 60 patients with follicular NHL undergoing ABMT NHL. The fact that patients with high-grade histologies are in which 18 patients relapsed in a median time of 14 likely to be cured if in CR 2 years post-BMT has important months with a range of 2 to 31 months. The European clinical and cost ramifications concerning patient surveilGroup for Bone Marrow Transplantation (EBMT) has lance. Analysis of mature data is the only way appropriate reported the results of 214 patients with lymphoblastic lymclinical guidelines may be formulated concerning the care phoma reported to the EBMT registry undergoing autologof patients after transplant. ous transplantation from 1981 to 1992. 23 The median time to relapse after ABMT was 6 months, and only one patient relapsed more than 36 months after ABMT. Our series had References far fewer numbers of patients transplanted with high grade histologies, and no patient with high-grade histology with respect to outcome after ABMT. Vose et al 5 published
